Update on the aducanumab (Aduhelm) saga, retirement, financial advice, cognitive health, excessive worrying, neurotech, and more

Welcome to a new edition of SharpBrains’ e‑newsletter, providing this time a summary of the saga around the FDA approval of aducanumab (Aduhelm) as a supposed treatment for Alzheimer’s Disease, plus a range of timely research findings and resources for lifelong brain health. First, below are some key reads to navigate “probably the worst drug approval decision in recent U.S. history” — Dr. Aaron Kesselheim, the Professor of Medicine at Harvard Medical School who resigned rom the FDA Advisory Committee in protest. #1. Growing backlash against the FDA approval of unproven Alzheimer’s treatment Aduhelm, by Biogen: “The Institute for Clinical and Economic Review (ICER) believes that the FDA, in approving aducanumab (Aduhelm by Biogen) for the treatment of Alzheimer’s disease, has failed in its responsibility to protect patients and families from unproven treatments with known harms.” #2. First, do no harm? Six reasons to approach anti-amyloid drug Aduhelm cautiously, if at all: “The FDA’s approval of Aduhelm raises more questions and creates more problems than a new drug approval should. It’s time for governmental, professional, and advocacy entities to step in where Biogen and the FDA have failed and explain to patients, caregivers, and clinicians how this drug is not the “new day” in the fight against Alzheimer’s disease and needs to be approached cautiously, if at all.” — Dr. Sam Gandy, Professor of Neurology and Psy...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Brain/ Mental Health Education & Lifelong Learning SharpBrains Monthly eNewsletter Technology & Innovation aducanumab Aduhelm Alzheimers-disease anti-amyloid drug Biogen Brain Teasers brain-teaser cognitive decline cognitive-exerci Source Type: blogs